Opinion|Videos|February 3, 2025
Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing
Author(s)Vivek Subbiah, MD, Lucio N. Gordan, MD
Panelists discuss how in-house testing facilities significantly enhance multidisciplinary coordination by enabling rapid result turnaround and real-time treatment adjustments. This streamlined process facilitates immediate care planning among specialists, leading to faster clinical decisions and reduced wait times. Studies demonstrate that on-site testing correlates with improved patient outcomes through earlier interventions, decreased length of stay, and enhanced treatment monitoring, ultimately supporting more efficient and responsive patient care delivery.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- How has in-house testing impacted multidisciplinary coordination and treatment planning at your institution?
- Discuss the impact of in-house testing on patient outcomes and overall quality of care.
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
The sNDA for elinzanetant seeks FDA approval for moderate to severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5